| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Gedeon Richter
Company Intelligence Report
Gedeon Richter is Hungary's oldest and largest pharmaceutical manufacturer,
dating back to 1901. This report provides an insight into the company,
reviewing its current business structure and activities.
Gedeon Richter's plant was nationalised in 1948, and it lost its Western
European export markets and its subsidiaries; the company instead focused on
its Eastern European markets, successfully entering the Polish and
Czechoslovak markets, and launching exports to the Soviet Union in 1954. By
1960, Gedeon Richter was the largest supplier of pharmaceutical products to
COMECON member countries and the Soviet Union. From the 1970s and through the
1980s, the company began again to expand into Western markets, and diversified
into agricultural chemicals and veterinary medicines. With the collapse of
COMECON in the early 1990s, the resulting loss of traditional markets, coupled
with the economic instability in the region hit Gedeon Richter severely. In
response, the company phased out its production of herbicides, veterinary
medicines and cosmetics, and upgraded its portfolio of human pharmaceuticals.
Gedeon Richter introduced a more market-led strategy and began to recover its
old markets, whilst continuing to increase its exports to Western markets.
Today, the company carries out research, development, manufacturing and
marketing of human finished drugs, active substances and intermediates.
Production in Hungary takes place in plants in Budapest and Dorog, but the
company also has production plants in Russia, Romania, Ukraine and India. The
company has marketing/wholesaling subsidiaries in the USA, France, Germany and
Ukraine, and owns a 50% stake in major Hungarian distributor, Medimpex. In
April 2001, Richter purchased a 5% equity stake in the Russian wholesaler,
Protek. Gedeon Richter has a presence in 30 countries. At the end of 2005, the
company employed 5,876 people.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- FINANCIAL RESULTS
- Geographic Segment Data
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- US deal with KV Pharmaceutical
- Themis and Gedeon Richter enter new product agreement
- Consortium bid for Hungaropharma successful
- IVAX enters agreements with Gedeon Richter
- Biogen International
- GZF Polfa
- Barr Laboratories
- Tax
- Litigation
- Amlodipine besylate
- Famotidine
- Enalapril
- CONTACT DETAILS
|
